Cargando…
Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value
In the light of recent advances in the immunotherapy field for breast cancer (BC) treatment, especially in the triple‐negative subtype, the identification of reliable biomarkers capable of improving patient selection is paramount, because only a portion of patients seem to derive benefit from this a...
Autores principales: | Miglietta, Federica, Griguolo, Gaia, Guarneri, Valentina, Dieci, Maria Vittoria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853089/ https://www.ncbi.nlm.nih.gov/pubmed/31444294 http://dx.doi.org/10.1634/theoncologist.2019-0197 |
Ejemplares similares
-
Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy
por: Vernaci, Grazia, et al.
Publicado: (2023) -
Validation of Residual Proliferative Cancer Burden as a Predictor of Long‐Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor‐Positive/Human Epidermal Growth Receptor 2‐Negative Breast Cancer
por: Miglietta, Federica, et al.
Publicado: (2020) -
Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications
por: Dieci, Maria Vittoria, et al.
Publicado: (2021) -
The Tumor Microenvironment of Primitive and Metastatic Breast Cancer: Implications for Novel Therapeutic Strategies
por: Zarrilli, Giovanni, et al.
Publicado: (2020) -
Prognostic impact of extracranial disease control in HER2+ breast cancer-related brain metastases
por: Bottosso, Michele, et al.
Publicado: (2023)